Phenindione anticoagulant

Description Results NMA

Death or dependency 1.11 [0.92; 1.34]

Non-fatal stroke, myocardial infarction or vascular death 0.70 [0.48; 1.04]

Deaths from any cause 1.12 [0.65; 1.90]

Vascular deaths 0.91 [0.50; 1.65]

Recurrent ischaemic/unknown stroke 0.51 [0.24; 1.07]

Symptomatic intracranial haemorrhage 2.55 [0.27; 23.77]

Any recurrent stroke or symptomatic intracranial haemorrhage 0.64 [0.33; 1.22]

Major extracranial haemorrhage ∞ [NaN; ∞]

Myocardial infarction 1.06 [0.30; 3.75]

Other embolic events 0.85 [0.05; 13.25]

Non-fatal stroke/intracranial haemorrhage or vascular death 0.72 [0.48; 1.09]

Deaths from any cause 1.41 [0.34; 5.85]

Vascular deaths 2.12 [0.42; 10.82]

Recurrent ischaemic/unknown stroke 1.48 [0.52; 4.22]

Symptomatic intracranial haemorrhage ∞ [NaN; ∞]

Any recurrent stroke or symptomatic intracranial haemorrhage 1.91 [0.71; 5.11]

Myocardial infarction 0.00 [0.00; NaN]

Non-fatal stroke/intracranial haemorrhage or vascular death 1.52 [0.65; 3.51]

phenindione thrombotest 10% to 25% of normal, started in hospital (n=-9)

vs.

placebo (n=-9)

single-blind

Parallel groups

Sample size: -9/-9

Primary endpoint:

FU duration: 22.7 months

phenindione, prothrombin-proconvertin test 10% to 20% (n=-9)

vs.

placebo (n=-9)

single-blind

Parallel groups

Sample size: -9/-9

Primary endpoint:

FU duration: 29.5 months

Phenindione (n=100)

vs.

No treatment (n=100)

Open

Sample size: 100/100

Primary endpoint:

FU duration: 3 months

Phenindione (n=38)

vs.

No treatment (n=38)

Open

Sample size: 38/38

Primary endpoint:

FU duration: 3–10 months